PATENT CLAIM ANALYSIS

Application Number: 15773798
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["514", "170000"]

Abstract:
The present invention relates to the use of non-bioconvertible C 3 -substituted pregnenolone derivatives of formula (I), with no significant affinity for hormonal receptors or receptors of the central nervous system, in the treatment of substance use disorders, and in particular of alcohol use disorder.

Claim (Index 11):
The method of  claim 1 , wherein said substance use disorder is selected from alcohol use disorder; cannabis use disorder; hallucinogens (including phencyclidine, ketamine, and LSD) use disorders; opioids (including codeine, fentanyl, heroin, morphine, opium, methadone, oxycodone, and hydrocodone) use disorders; sedative, hypnotic or anxiolytic medications (including barbiturates and benzodiazepines) use disorders; stimulants (including nicotine, amphetamine, and methylphenidate) use disorders; and inhalants (such as glue, shoe polish, toluene, spray paints, gasoline, and lighter fluid) use disorders.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 93.0
- Lexical Diversity: 1.30769
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15444778', '15012471', '14950178', '13666663', '12232993']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7819010257319089
- 35 USC 102 Novelty (BERT): 0.5272639576101191
- Combined Prediction Score: 0.7564373189197299
- Mean Citation Score: 276.51452800000004
- Max Citation Score: 335.08203
- Similarity Product: 232.7871193653596

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test